CD19 and prostate carcinoma: In addition to antibody production, Ammirante et al. demonstrated that tumor-infiltrating mature B2 cells (CD19+ B220+ CD5− CD11b−) produce lymphotoxin (LT) which is crucial for castration-resistant prostate cancer tumor development.